iPrevail est une plateforme de santé mentale et de bien-être alimentée par l'IA offrant un soutien à la demande. Elle fournit des programmes personnalisés basés sur la Thérapie Cognitive et Comportementale (TCC), du coaching par les pairs et une communauté de soutien pour aider les utilisateurs à gérer le stress, l'anxiété, la dépression et d'autres défis émotionnels de manière efficace et confidentielle.
PsyFly est un psychologue IA disponible 24h/24 et 7j/7, offrant un soutien psychologique instantané, professionnel et confidentiel. Il adopte une approche empathique pour aider les utilisateurs à tout moment, jour et nuit, sans rendez-vous.
Aperçu du produit
iprevail Aperçu du produit
iPrevail est une plateforme de santé mentale et de bien-être alimentée par l'IA offrant un soutien à la demande. Elle fournit des programmes personnalisés basés sur la Thérapie Cognitive et Comportementale (TCC), du coaching par les pairs et une communauté de soutien pour aider les utilisateurs à gérer le stress, l'anxiété, la dépression et d'autres défis émotionnels de manière efficace et confidentielle.
PsyFly Aperçu du produit
PsyFly est un psychologue IA disponible 24h/24 et 7j/7, offrant un soutien psychologique instantané, professionnel et confidentiel. Il adopte une approche empathique pour aider les utilisateurs à tout moment, jour et nuit, sans rendez-vous.
Detailed feature comparison
| Feature | iprevail | PsyFly |
|---|---|---|
| Catégorie principale | Apprentissage en ligne | Thérapie |
| Ajouté | 2025-08-15 | 2025-10-24 |
| Tarification | Freemium | Freemium |
| Site officiel | www.iprevail.com | psyfly.netlify.app |
| Type de produit | Site web | Site web |
| Performance data | ||
| Note utilisateur | Non vérifié | Non vérifié |
| Commentaires | 0 | 0 |
| Visites mensuelles | 17K | 3.6K |
| Croissance mensuelle | 0.9% | Non vérifié |
| Favoris | 128 | 111 |
| Details | Voir les détails | Voir les détails |
iprevail vs PsyFly monthly traffic
Compare iprevail and PsyFly by monthly reach, traffic trend, visit depth, top regions, and acquisition sources.
How to interpret the traffic data
In the iprevail vs PsyFly monthly traffic comparison, iprevail currently shows 17K visits and PsyFly shows 3.6K; iprevail has about 4.8 times the visible traffic of PsyFly, an absolute difference of about 13.4K visits. This reflects visible reach, not feature quality or paid users.
Only iprevail has complete third-party traffic details; PsyFly uses visits recorded inside ToolMage. These scopes cannot estimate market share directly, and on-site views should not be treated as the product’s total website traffic.
iprevail monthly traffic:
Latest traffic
Monthly traffic trend
- 2025/9: 18.2K Visites mensuelles
- 2026/1: 33.5K Visites mensuelles
- 2026/2: 18.2K Visites mensuelles
- 2026/3: 13.8K Visites mensuelles
- 2026/4: 16.8K Visites mensuelles
- 2026/5: 17K Visites mensuelles
Principales régions
Top 5 countries/regions
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 100% | 17K |
Sources de trafic
| Source type | Percentage | Traffic |
|---|---|---|
| Direct | 54.81% | 9.3K |
| 26.79% | 4.5K | |
| Référence | 18.4% | 3.1K |
Mots-clés
PsyFly monthly traffic:
Latest traffic
Usage comparison
Compare the core capabilities of iprevail and PsyFly
iprevail Core features
PsyFly Core features
Use cases
iprevail Use cases
PsyFly Use cases
Best suited roles
iprevail Best suited roles
PsyFly Best suited roles
iprevail vs PsyFly:In-depth comparison and selection guidance
First decide whether the products solve the same kind of need
This in-depth iprevail vs PsyFly comparison uses only the product records, taxonomy, audience, traffic, and community signals available on this page. iprevail is primarily listed under “Apprentissage en ligne”, while PsyFly is primarily listed under “Thérapie”, so the first decision is whether your actual task matches their recorded scope.
The structured fields currently show these decision-relevant differences: Primary category (iprevail: Apprentissage en ligne; PsyFly: Thérapie); Monthly visits (iprevail: 17K; PsyFly: 3.6K); Favorites (iprevail: 128; PsyFly: 111); Website (iprevail: www.iprevail.com; PsyFly: psyfly.netlify.app); Added (iprevail: 2025-08-15; PsyFly: 2025-10-24). These facts are more useful for selection than brand visibility alone.
What market visibility and monthly traffic mean
In the iprevail vs PsyFly monthly traffic comparison, iprevail currently shows 17K visits and PsyFly shows 3.6K; iprevail has about 4.8 times the visible traffic of PsyFly, an absolute difference of about 13.4K visits. This reflects visible reach, not feature quality or paid users.
Only iprevail has complete third-party traffic details; PsyFly uses visits recorded inside ToolMage. These scopes cannot estimate market share directly, and on-site views should not be treated as the product’s total website traffic.
The current traffic scope is not sufficient for a reliable product ranking. Treat monthly visits as a market-interest signal, then decide using taxonomy, use cases, pricing, and a like-for-like trial rather than reading exposure as product capability.
Product positioning, use cases, and roles
iprevail and PsyFly currently overlap in shared tags: thérapie en ligne, Auto-soin et bien-être. This can place both on the same shortlist, but it does not prove equal implementation, depth, or cost.
iprevail's unique categories/tags are Apprentissage en ligne, Santé Mentale, Développement Personnel, Soutien à l'anxiété, Thérapie Cognitivo-Comportementale, Thérapie cognitivo-comportementale, Aide à la Dépression et santé mentale; PsyFly's are Thérapie, Soutien Émotionnel, Soins personnels, Psychologue IA, Thérapie par IA, Thérapie confidentielle, Soutien émotionnel et conseil instantané. These unique fields are the strongest differentiators: validate the product whose recorded scope matches the task instead of following traffic alone.
What ratings, comments, and favorites can tell you
iprevail has no verified rating, 0 comments, 128 favorites, and 141 likes;PsyFly has no verified rating, 0 comments, 111 favorites, and 119 likes。
Neither product has enough rating or comment samples for a credible reputation ranking.
Selection guidance by actual need
When to evaluate iprevail first
Put iprevail on the priority trial list when the task aligns with “Apprentissage en ligne” and especially Apprentissage en ligne, Santé Mentale, Développement Personnel, Soutien à l'anxiété, Thérapie Cognitivo-Comportementale et Thérapie cognitivo-comportementale. This follows recorded positioning and does not imply unlisted capabilities are absent.
iprevail also currently records: pricing is freemium, product type is website, 17K verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
When to evaluate PsyFly first
Put PsyFly on the priority trial list when the task aligns with “Thérapie” and especially Thérapie, Soutien Émotionnel, Soins personnels, Psychologue IA, Thérapie par IA et Thérapie confidentielle, or the users include Personnes recherchant un soutien en santé mentale, Personnes à la recherche d'outils de soins personnels confidentiels et Utilisateurs ayant besoin d'un accompagnement émotionnel immédiat. This follows recorded positioning and does not imply unlisted capabilities are absent.
PsyFly also currently records: pricing is freemium, product type is website, 3.6K on-site monthly views, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
How to validate the recommendation before deciding
The available data describes positioning, public visibility, and community signals, but it cannot prove output quality, speed, integration effort, privacy, or long-term cost in your workflow. Before deciding, run the same representative tasks in iprevail and PsyFly, then record completion time, accuracy, manual corrections, and the real paid threshold. A like-for-like trial turns this comparison into a defensible adoption decision.




